## **Abhay Sagare**

## List of Publications by Citations

Source: https://exaly.com/author-pdf/6309192/abhay-sagare-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39 10,477 34 42 g-index

42 12,298 15.3 6.21 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
39	Blood-brain barrier breakdown in the aging human hippocampus. <i>Neuron</i> , <b>2015</b> , 85, 296-302	13.9	1023
38	Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 133-150	15	991
37	Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. <i>Neuron</i> , <b>2010</b> , 68, 409-27	13.9	963
36	Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. <i>Nature</i> , <b>2012</b> , 485, 512-6	50.4	813
35	LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. <i>Neuron</i> , <b>2004</b> , 43, 333-44	13.9	661
34	Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. <i>Nature Medicine</i> , <b>2019</b> , 25, 270-276	50.5	577
33	apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 4002-13	15.9	509
32	Transport pathways for clearance of human Alzheimerঙ amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2007</b> , 27, 909-18	7.3	495
31	P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 3285-90	15.9	459
30	A multimodal RAGE-specific inhibitor reduces amyloid Emediated brain disorder in a mouse model of Alzheimer disease. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 1377-92	15.9	385
29	GLUT1 reductions exacerbate Alzheimerঙ disease vasculo-neuronal dysfunction and degeneration. <i>Nature Neuroscience</i> , <b>2015</b> , 18, 521-530	25.5	350
28	ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. <i>Nature Neuroscience</i> , <b>2008</b> , 11, 420-2	25.5	341
27	Clearance of amyloid-beta by circulating lipoprotein receptors. <i>Nature Medicine</i> , <b>2007</b> , 13, 1029-31	50.5	330
26	Central role for PICALM in amyloid-Iblood-brain barrier transcytosis and clearance. <i>Nature Neuroscience</i> , <b>2015</b> , 18, 978-87	25.5	265
25	Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. <i>Nature Medicine</i> , <b>2005</b> , 11, 959-65	50.5	233
24	Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. <i>Nature Medicine</i> , <b>2018</b> , 24, 326-337	50.5	211
23	SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. <i>Nature Cell Biology</i> , <b>2009</b> , 11, 143-53	23.4	202

## (2020-2005)

22	IgG-assisted age-dependent clearance of Alzheimerld amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 11495-503	6.6	198
21	Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer <b>u</b> amyloid Epeptide elimination from the brain. <i>Journal of Neurochemistry</i> , <b>2010</b> , 115, 1077-89	6	173
20	The pericyte: a forgotten cell type with important implications for Alzheimer以 disease?. <i>Brain Pathology</i> , <b>2014</b> , 24, 371-86	6	158
19	Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E1035	-42 <sup>1.5</sup>	150
18	The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer <b>'</b> disease. <i>Current Pharmaceutical Design</i> , <b>2008</b> , 14, 1601-5	3.3	142
17	Impaired vascular-mediated clearance of brain amyloid beta in Alzheimerld disease: the role, regulation and restoration of LRP1. <i>Frontiers in Aging Neuroscience</i> , <b>2015</b> , 7, 136	5.3	117
16	Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. <i>Blood</i> , <b>2010</b> , 115, 4963-72	2.2	86
15	Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. <i>JAMA Neurology</i> , <b>2013</b> , 70, 1198-200	17.2	83
14	Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimerld disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2015</b> , 35, 1055-68	7.3	74
13	Shedding of soluble platelet-derived growth factor receptor-Ifrom human brain pericytes. <i>Neuroscience Letters</i> , <b>2015</b> , 607, 97-101	3.3	71
12	Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2009</b> , 29, 25-33	7.3	54
11	Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-lis an early biomarker for mild cognitive impairment preceding Alzheimerঙ disease. <i>Journal of Alzheimer</i> ঙ <i>Disease</i> , <b>2011</b> , 24, 25-34	4.3	53
10	Role of clusterin in the brain vascular clearance of amyloid- $\square$ <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 8681-8682	11.5	52
9	Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. <i>Journal of Neuroscience Methods</i> , <b>2004</b> , 138, 233-42	3	48
8	Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 15521-34	6.6	45
7	Impaired spine formation and learning in GPCR kinase 2 interacting protein-1 (GIT1) knockout mice. <i>Brain Research</i> , <b>2010</b> , 1317, 218-26	3.7	37
6	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 279-293	16.6	35
5	Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. <i>EBioMedicine</i> , <b>2020</b> , 59, 102883	8.8	30

4	A lipoprotein receptor cluster IV mutant preferentially binds amyloid-land regulates its clearance from the mouse brain. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 15154-66	5.4	29
3	From the liver to the blood-brain barrier: an interconnected system regulating brain amyloid- levels. <i>Journal of Neuroscience Research</i> , <b>2011</b> , 89, 967-8	4.4	21
2	Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. <i>Neuropharmacology</i> , <b>2018</b> , 134, 293-301	5.5	11
1	Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. <i>Journal of Experimental Medicine</i> , <b>2022</b> , 219,	16.6	2